Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) saw a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 4,200 shares, a growth of 133.3% from the October 31st total of 1,800 shares. Based on an average trading volume of 26,600 shares, the short-interest ratio is presently 0.2 days.

Scinai Immunotherapeutics Price Performance

SCNI stock traded down $0.02 during midday trading on Thursday, reaching $3.46. 40,172 shares of the stock were exchanged, compared to its average volume of 298,630. Scinai Immunotherapeutics has a 52 week low of $2.23 and a 52 week high of $8.92. The company has a fifty day moving average price of $3.49 and a 200 day moving average price of $3.69. The stock has a market capitalization of $2.01 million, a PE ratio of -0.01 and a beta of 2.46.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.